Veradermics Incorporated Common Stock (MANE)
Stock · NYSE · Health Care
$109.04as of 10/16/2026
Price chart
Active signals
Support level
$97.88
Industry
Biotechnology: Pharmaceutical Preparations
About MANE
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDM…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 37
- Website
- www.veradermics.com/
Fundamentals
- 1-day range
- $108.08$114.25
- Market cap
- $4.54B
- P/E (trailing)
- —
- P/E (forward)
- -40.43
- EPS (trailing)
- $-3.78
- Dividend yield
- —
- Beta
- 0.02
- Avg. volume
- 779.4K
52-week range
$32$136.72
Next earnings: November 12, 2026 · EPS estimate $-0.60
Forecasts
6 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$182
+66.9%
Median
$167
+53.2%
Low
$135
+23.8%
Veradermics Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- MANEVeradermics Incorporated Common Stock$108.82▼ 5.43%Market cap $4.54BP/E —$32$136.72
- EWTXEdgewise Therapeutics Inc. Common Stock$37.19▼ 2.64%Market cap $4.78BP/E —$14.25$48.51
- INDVIndivior Pharmaceuticals Inc. Common Stock$32.45▼ 3.48%Market cap $4.82BP/E 11.25$23.67$42.81
- DYNDyne Therapeutics Inc. Common Stock$14.25▼ 6.80%Market cap $4.83BP/E —$13.88$27.31
- PBLSParabilis Medicines Inc. Common Stock$22.75▼ 9.65%Market cap $4.23BP/E —$24.51$42.49
- ACADACADIA Pharmaceuticals Inc. Common Stock$19.12▼ 2.99%Market cap $4.87BP/E 8.79$18.39$30.96
- TNGXTango Therapeutics Inc.$22.04▼ 2.91%Market cap $4.19BP/E —$6.69$34.39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MANE Veradermics Incorporated Common Stock | $4.54B | — | $108.82 | ▼ 5.43% | $32$136.72 |
| EWTX Edgewise Therapeutics Inc. Common Stock | $4.78B | — | $37.19 | ▼ 2.64% | $14.25$48.51 |
| INDV Indivior Pharmaceuticals Inc. Common Stock | $4.82B | 11.25 | $32.45 | ▼ 3.48% | $23.67$42.81 |
| DYN Dyne Therapeutics Inc. Common Stock | $4.83B | — | $14.25 | ▼ 6.80% | $13.88$27.31 |
| PBLS Parabilis Medicines Inc. Common Stock | $4.23B | — | $22.75 | ▼ 9.65% | $24.51$42.49 |
| ACAD ACADIA Pharmaceuticals Inc. Common Stock | $4.87B | 8.79 | $19.12 | ▼ 2.99% | $18.39$30.96 |
| TNGX Tango Therapeutics Inc. | $4.19B | — | $22.04 | ▼ 2.91% | $6.69$34.39 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Veradermics: The Momentum Is Building, But Know This Before H2 2026 ReadoutsSeekingAlpha · 10/9/2026
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · 10/8/2026
- Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On ThursdayBenzinga · 10/8/2026
- Veradermics: Buy Before The CatalystsSeekingAlpha · 9/18/2026
- HQL: The Rally That Makes Growth Harder (Rating Downgrade)SeekingAlpha · 9/15/2026
- Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as OzempicYahoo · 9/12/2026
Insider Activity
Insider Actions →Acquired
335.9K
Disposed
796.7K
- Hollander David · September 1, 2026 · Grant19.3K
- Hollander David · September 1, 2026 · Grant9.7K
- MONTANOVA CAPITAL, LLC · August 20, 2026 · X151.0K
- MONTANOVA CAPITAL, LLC · August 20, 2026 · X149.0K
- MONTANOVA CAPITAL, LLC · August 19, 2026 · Sale59.4K @ $107.25
- MONTANOVA CAPITAL, LLC · August 19, 2026 · Sale690.6K @ $107.25
- Timothy August Durso · August 17, 2026 · Option Exercise3.5K @ $12.19
- Timothy August Durso · August 17, 2026 · Sale161 @ $111.28
- Timothy August Durso · August 17, 2026 · Sale2.3K @ $109.34
- Timothy August Durso · August 17, 2026 · Sale16.8K @ $108.38
- Timothy August Durso · August 17, 2026 · Sale16.3K @ $107.52
- Timothy August Durso · August 17, 2026 · Sale7.9K @ $106.71
- Reid Alexander Waldman · August 17, 2026 · Option Exercise3.5K @ $12.19
- Reid Alexander Waldman · August 17, 2026 · Sale249 @ $111.28
- Reid Alexander Waldman · August 17, 2026 · Sale3.0K @ $109.38
Institutional Ownership
March 31, 2026
- Total shares held
- 24.84M
- Total value held
- $1.57B
- Institutional holders
- 77
Top holders this quarter
- Unknown4.17M
- Unknown2.40M
- Unknown1.83M
- Unknown1.79M
- Unknown1.69M
- Unknown1.51M
- Unknown1.10M
- Unknown1.05M
- Unknown731.1K
- Unknown699.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Veradermics Momentum Builds, But H2 2026 Readouts Caution
Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.
Veradermics Momentum Builds, But H2 2026 Readouts Caution. Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.